ABSTRACT
Sildenafil has been thoroughly studied in 74 registered double-blind, placebo-controlled clinical trials assessing the efficacy and safety of the drug in a total of more than 16 000 men with erectile dysfunction (ED). However, practicing urologists have some questions regarding administering the drug in patients with multiple comorbidities. In this review, on a par with the now "classic" research, we outline the latest updates of meta-analyzes and comparative studies relating to the use of sildenafil in different groups of patients. We also discuss the problem of self-discontinuation of sildenafil therapy and the possible risks of using counterfeit phosphodiesterase type 5 inhibitors (PDE-5i).
Subject(s)
Phosphodiesterase 5 Inhibitors/therapeutic use , Sildenafil Citrate/therapeutic use , Counterfeit Drugs/therapeutic use , Humans , Male , Medication Adherence , Meta-Analysis as TopicABSTRACT
Sportsman-fencers (683 persons) of various qualification and types of fencing (sabre fencers, foil fencers, swordsmen) have been roentgenologically examined. Of them 97 have been examined for the second time in a year. For a comparison 204 persons nonsportsmen have been examined. Increased specialized loadings of chop-push character, peculiar for fencing, accelerate processes of bone sinostosis and result in certain morphological changes in the components of the knee joint: the joint cartilage becomes thinner (as demonstrates the roentgenologically measured joint cleft), periostal osteogenesis on the surface of epiphyses, endothelial osteogenesis in the bone diaphyses become activated.
